Use the addictive nature of pancreatic cancer to develop new anti-cancer therapies

Cancer cells are often described as "bad" or "metastatic" cells, and recent research by scientists at cold spring harbor laboratories in the United States has found that in some of the deadliest cases of pancreatic cancer, these rebellious cells may exhibit an unexpected addiction, according to a study published in the international journal Cell Reports, in which researchers investigated whether using such addiction could end pancreatic cancer once and for all.
researcher Professor Chris Vakoc said: 'In this study, we looked at the addictive behaviour of cancer cells in the most invasive pancreatic cancer subtype, which has a very high fatality rate, with an average survival rate of about two years after diagnosis, but a well-known subsecret of pancreatic cancer dies before the end of the first year of diagnosis;
The researchers then identified a gene called TP63 (Tumor Protein 63, Tumor-Protein 63), which is particularly expressed in malignant forms of pancreatic cancer; The production of scaly epithellal cells is necessary, and scaly epithellal cells are the longer thin cells needed for a class of skin formation, and when the researchers noticed that P63 also works in the pancreas, they seemed to find something suspicious: that P63 promotes pancreatic cell growth to become normal cells.
The researchers then found that having this scaly cell-promoting gene can be extremely active in tumors, making it easy for new isolated cells to produce and spread to other parts of the body; however, when things get easy, there is often a "trap" that you can't expect, and the researchers point out that cancer cells are dependent on P63, and that cancer cells actually need the protein to continue growing, so researchers need to find a way to suppress P63 activity as a way to treat pancreatic cancer patients.
In addition, in this study, the researchers explained why TP63 is activated in pancreatic tissue in a particular patient, and if researchers can block TP63 activation, it may be possible to develop new treatments that effectively treat pancreatic cancer patients. (Bio Valley)